Karuna Therapeutics (KRTX) Stock Price, News & Analysis

Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $329.83 to $329.83
• 50-Day Range: $313.97 to $329.83
• 52-Week Range: $158.38 to $329.99
• Volume: 5 shs
• Average Volume: 832,048 shs
• Market Capitalization: $12.58 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $330.00
• Consensus Rating: Hold

KRTX Stock Analysis - Frequently Asked Questions

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. Karuna Therapeutics's revenue for the quarter was down 100.0% compared to the same quarter last year.

When did Karuna Therapeutics IPO?

Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Palo Alto Networks (PANW), Salesforce (CRM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 2/22/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KRTX
• CUSIP: N/A
• CIK: 1771917
• Web: karunatx.com
• Phone: (857) 449-2244
• Fax: N/A
• Employees: 339
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $330.00
• High Stock Price Target: $330.00
• Low Stock Price Target: $330.00
• Potential Upside/Downside: +0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-433,680,000.00
• Net Margins: N/A
• Pretax Margin: -66,209.48%
• Return on Equity: -31.63%
• Return on Assets: -30.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.31
• Quick Ratio: 19.31

Sales & Book Value

• Annual Sales: $654,000.00
• Price / Sales: 19,239.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $33.24 per share
• Price / Book: 9.92

Miscellaneous

• Outstanding Shares: 38,148,000
• Free Float: 33,157,000
• Market Cap: $12.58 billion
• Optionable: Optionable
• Beta: 1.18